EUVIMEDEUVIMED entdecken
Übersichtsarbeit

ECM-responsive nanomedicine to enhance immunotherapy in pancreatic cancer

Li Li, Junxiong Wen, Hao Xu, Hongyuan Yu, Xue Bai, Yue Zhang

Colloids and Surfaces B: Biointerfaces · 2026

DOI: 10.1016/j.colsurfb.2025.115356 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Colloids and Surfaces B: Biointerfaces, 2026. Verfasst von Li Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Immunotherapy, Pancreatic Neoplasms, Extracellular Matrix, Nanomedicine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 126 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most treatment-resistant malignancies, primarily attributed to its dense and fibrotic extracellular matrix (ECM), which impedes both immune cell infiltration and drug delivery. Despite the remarkable success of immunotherapy in other cancer types, its efficacy in PDAC has been significantly compromised by the immune-exclusion barrier. Recent advancements in nanomedicine offer a compelling strategy to overcome this hurdle through the development of ECM-responsive delivery systems. These platforms are engineered to respond to ECM-specific triggers such as hyaluronidase or matrix metalloproteinases, enabling localized degradation of the tumor stroma while simultaneously releasing immunostimulatory agents. This review summarizes the unique ECM biology of PDAC, current limitations of immunotherapy, and recent breakthroughs in stimuli-responsive nanotechnology. This study also comprehensively discusses design principles, preclinical validation outcomes, translational challenges, and emerging strategies integrating ECM modulation with next-generation immune activation. ECM-responsive nanomedicine represents a transformative paradigm in stroma-immune co-engineering and offers a promising avenue for unlocking immunotherapy in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyPancreatic NeoplasmsExtracellular MatrixNanomedicineCarcinoma, Pancreatic DuctalHumansAnimalsDrug Delivery Systems

Stichwörter der Autor:innen

ECM-responsive nanomedicineExtracellular matrixHyaluronidase-sensitive nanoparticlesPancreatic ductal adenocarcinomaTumor microenvironment

Autor:innen und Institutionen

  • Department of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Gastrointestinal Surgery, The First Hospital of China Medical University, Nanjing Street 155, Shenyang 110001, China.
  • Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China. Electronic address: yuhongyuan_1984@163.com.
  • Department of Ophthalmology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China. Electronic address: baixueys@163.com.
  • Department of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: zhangyue_cmu2024@163.com.

Zitieren

APA

Li, L., Wen, J., Xu, H., Yu, H., Bai, X., & Zhang, Y. (2026). ECM-responsive nanomedicine to enhance immunotherapy in pancreatic cancer. Colloids and Surfaces B: Biointerfaces. https://doi.org/10.1016/j.colsurfb.2025.115356

Vancouver

Li L, Wen J, Xu H, Yu H, Bai X, Zhang Y. ECM-responsive nanomedicine to enhance immunotherapy in pancreatic cancer. Colloids and Surfaces B: Biointerfaces. 2026. doi:10.1016/j.colsurfb.2025.115356

BibTeX
@article{Li2026,
  author = {Li, Li and Wen, Junxiong and Xu, Hao and Yu, Hongyuan and Bai, Xue and Zhang, Yue},
  title = {ECM-responsive nanomedicine to enhance immunotherapy in pancreatic cancer},
  journal = {Colloids and Surfaces B: Biointerfaces},
  year = {2026},
  doi = {10.1016/j.colsurfb.2025.115356}
}
Kostenlos starten →